Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of recommending that COVID-19 vaccines for 2025-26 should target newer strains of the JN.1 variant.

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

The FDA will narrow its approval for updated coronavirus vaccines, marking a significant shift in the agency’s approach to green-lighting shots that have been recommended broadly to the public.

Trump administration to restrict COVID vaccines to seniors and high-risk groups, pending more data for everyone else.

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the “Company”), comments on the new COVID Vaccine policy adopted by the US FDA. The new FDA COVID Vaccine Booster Shots policy [1] is based on the findings that the groups that benefit from repeat

As the Trump administration’s FDA moves to limit approval for COVID-19 booster shots, millions of Americans under 65 may find themselves without access this fall. However, until Friday, there’s still time to influence this decision, pro or con, through the FDA’s public comment portal.

Moderna said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot,